Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

NCT04479306 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Alisertib
DRUG: Osimertinib
DRUG: Sapanisertib

Sponsor

M.D. Anderson Cancer Center